Meeting
2020 ASCO Virtual Scientific Program
Subcutaneous daratumumab in patients with multiple myeloma who have been previously treated with intravenous daratumumab: A multicenter, randomized, phase II study (LYNX).
Authors
Nizar J. Bahlis
University of Calgary, Arnie Charbonneau Cancer Institute, Calgary, AB, Canada
Nizar J. Bahlis , Jeffrey A. Zonder , Susan Wroblewski , Ming Qi , Thomas Renaud , Carolyn Chang Jackson , Thierry Facon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03871829
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS8553)
DOI
10.1200/JCO.2020.38.15_suppl.TPS8553
Abstract #
TPS8553
Poster Bd #
453
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
First Author: Ajai Chari
Poster
2014 ASCO Annual Meeting
Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma.
First Author: Torben Plesner
Poster
2023 ASCO Annual Meeting
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.
First Author: Paul G. Richardson
Poster
2023 ASCO Annual Meeting
Ixazomib and daratumumab without dexamethasone (I-Dara) in elderly frail patients with RRMM: Results of the multicenter phase 2 study (IFM 2018-02) of the Intergroupe Francophone du Myélome (IFM).
First Author: Cyrille Touzeau